Anti-Schistosomiasis Sm14-vaccine in Senegal
Schistosomiasis Mansoni, Schistosomiasis Haematobium, Vaccination; Infection
About this trial
This is an interventional prevention trial for Schistosomiasis Mansoni
Eligibility Criteria
Inclusion Criteria: Man living in villages in the Saint Louis region where schistosomiasis is endemic. Having an infectious history of schistosomiasis. Adult between 18 and 49 years old at the time of the first injection. Have received pre-treatment with PZQ four to eight weeks before inclusion. Consent signed by the volunteer after information. Satisfactory state of health, confirmed on clinical examination and following biological assessment (Vpi / W-1). Available for the duration of the trial. To be negative to the Covid-19 antigenic test Exclusion Criteria (Non inclusion criteria) : Subject not meeting one of the inclusion criteria. Participation to a previous anti-schistosomiasis vaccine clinical trial. Participation in another ongoing clinical research Current or previous chronic administration (defined as more than 14 days) of immunosuppressive drugs or other immune modulating drugs. Known hypersensitivity to any component present in the Sm14 vaccine, or to any given vaccine, and / or history of allergic disease. Acute illness at the time of inclusion. Other conditions which, according to the PI, can potentially represent a danger to the subject to be included.
Sites / Locations
- Biomedical Research Center EPLSRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Arm 1 (Group Vacc3)
Arm 2 (Group Vacc2+1)
Volunteers will receive three (3) intramuscular injections into the deltoid muscle of 0.5mL of of the Sm14+ GLA-SE vaccine on D0, W4 and W8. (D = Day; W = Week). (Vaccination schedule used in previous phases).
Volunteers will receive three (3) intramuscular injections of the Sm14+ GLA-SE vaccine into the deltoid muscle of 0.5mL of vaccine on D0, W4 and W20 (new vaccination schedule).